Generic Kaletra ( Lopinavir/Ritonavir )

Buy Generic Kaletra (Lopinavir/Ritonavir) without prescription in Canada

Kaletra (Lopinavir/Ritonavir 200/50 mg): Comprehensive Patient Information for Canada

Basic Product Information

Mechanism of Action

In simple terms: Kaletra is a combination HIV medicine that contains two drugs working together. Lopinavir is the active antiviral that stops the HIV virus from making copies of itself by blocking an enzyme the virus needs to mature. Ritonavir is a booster that does not fight the virus directly at this dose but blocks the liver from breaking down lopinavir, keeping its levels high in the blood so it can work effectively around the clock.

For specialists: Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. Inhibition of HIV protease prevents cleavage of the gag-pol polyprotein, resulting in the production of immature, non-infectious viral particles. Ritonavir is a potent CYP3A inhibitor that inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir. The co-formulation exploits the pharmacokinetic boosting effect of ritonavir to maintain therapeutic lopinavir concentrations with twice-daily dosing. Ritonavir does not contribute meaningfully to the antiviral effect at the booster dose.

Pharmacokinetics

• Absorption: Lopinavir is rapidly absorbed after oral administration. The bioavailability of the tablet formulation is enhanced compared to the older soft-gel capsule when taken without food. The tablet can be taken with or without food. After a 400/100 mg dose, approximately 10.4% and 82.6% of the administered dose is recovered in urine and feces, respectively. Unchanged lopinavir accounted for approximately 2.2% and 19.8% of the dose in urine and feces, respectively.
• Metabolism: Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, primarily by CYP3A4. Ritonavir, co-formulated in the product, inhibits CYP3A-mediated metabolism of lopinavir, substantially increasing lopinavir plasma concentrations and prolonging its elimination. After repeated dosing, less than 3% of the lopinavir dose is excreted unchanged in the urine.
• Elimination: The effective (peak-to-trough) half-life of lopinavir over a 12-hour dosing interval averages 5–6 hours. The apparent oral clearance (CL/F) of lopinavir is 6–7 L/h. Steady-state lopinavir plasma concentrations are 15- to 20-fold higher than those of ritonavir in HIV-infected patients.
• Onset of Action: Antiviral activity begins after the drug reaches therapeutic plasma concentrations, typically within the first few days of treatment. Maximal virological suppression is usually achieved over weeks to months with consistent adherence.
• Duration of Action: With twice-daily dosing, therapeutic lopinavir concentrations are maintained throughout the 12-hour dosing interval. Once-daily dosing (800/200 mg) is associated with approximately 50% lower trough concentrations compared to twice-daily dosing and is only appropriate for certain treatment-naïve patients.

Uses in Daily Life and Best Practice Advice

Kaletra is prescribed in Canada as part of combination antiretroviral therapy (ART) for the treatment of HIV-1 infection. Your HIV specialist will determine the appropriate use and dose based on your treatment history and viral load.

• Typical Uses: Treatment of HIV-1 infection in adults and in pediatric patients 14 days of age and older, in combination with other antiretroviral agents. Kaletra is used in both treatment-naïve and treatment-experienced patients, although its role has diminished in recent years with the availability of newer, better-tolerated antiretroviral agents.
• Administration: Tablets should be swallowed whole and may be taken with or without food. The oral solution must be taken with food to improve absorption. Do not crush, chew, or split the tablets unless directed by your pharmacist. The oral solution should be measured using the provided calibrated dosing syringe.
• Monitoring: Regular monitoring of viral load, CD4+ count, liver enzymes, lipid profile, and blood glucose is essential during treatment. Your HIV specialist will also monitor for drug interactions and adherence. Do not miss doses, as missing doses can lead to the virus becoming resistant to lopinavir and other similar drugs.
• Do Not Stop Without Medical Advice: Do not stop taking Kaletra without consulting your HIV specialist. Stopping treatment can cause your viral load to increase and your immune system to be further damaged.

Morning vs. Evening Dosing

Kaletra is typically taken twice daily, approximately 12 hours apart. There is no specific clinical recommendation for morning versus evening dosing. Some patients find that taking the evening dose with a meal improves tolerability. Always follow the schedule recommended by your HIV specialist.

• Twice Daily (Standard): The standard dose is 400/100 mg (two 200/50 mg tablets) twice daily, approximately 12 hours apart.
• Once Daily (Selected Patients): In certain treatment-naïve patients, a once-daily dose of 800/200 mg (four 200/50 mg tablets) may be used, but this is not appropriate for all patients and should only be used if specifically directed by your HIV specialist.
• Consistency: Take Kaletra at the same times each day to maintain therapeutic blood levels and prevent viral resistance.
• Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.

Administration With or Without Food

Kaletra 200/50 mg tablets may be taken with or without food. The oral solution, however, must be taken with food to ensure adequate absorption. Taking the oral solution on an empty stomach reduces its bioavailability and may compromise treatment efficacy.

• Swallow the tablets whole with a full glass of water. Do not crush, chew, or split the tablets.
• Tablets may be taken with or without food.
• The oral solution must be taken with food.
• Shake the oral solution bottle well before each use. Measure doses accurately using the provided syringe.
• Avoid drinking alcohol while taking Kaletra, as alcohol may worsen liver-related side effects and increase the risk of pancreatitis.

Interaction Warnings

Indications for Kaletra

"Off-label" means use outside the official approved indication, usually based on current medical guidelines and scientific evidence.

Dosing According to Clinical Indication

Doses should always be adjusted according to the advice of your HIV specialist and depending on your health condition, viral load, and other medications. Do not change your dose without medical advice.

Side Effects and Safety Profile

Guidelines for Correct Use

• Take Kaletra exactly as prescribed by your HIV specialist. Do not change your dose without medical advice.
• Swallow tablets whole with a full glass of water. Do not crush, chew, or split the tablets.
• Tablets may be taken with or without food. The oral solution must be taken with food.
• Do not miss doses. Missing doses can lead to HIV resistance and reduce future treatment options.
• Do not stop taking Kaletra without consulting your HIV specialist.
• Avoid alcohol while taking Kaletra, as it may worsen liver side effects and increase the risk of pancreatitis.
• Keep all medical appointments for monitoring of viral load, CD4+ count, liver function, and lipid levels.
• Inform every healthcare provider (including dentists, surgeons, and pharmacists) that you are taking Kaletra, as it interacts with many medications.
• If you are pregnant, planning to become pregnant, or breastfeeding, consult your HIV specialist before use.
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double the dose.
• Store at room temperature (20–25°C) in a dry place. Keep out of reach of children.

Alternative Treatment Options

• Integrase Inhibitor-Based Regimens (e.g., Dolutegravir, Bictegravir, Raltegravir): These are now preferred first-line regimens in most Canadian and international guidelines due to superior efficacy, better tolerability, and fewer drug interactions compared with protease inhibitor-based regimens like Kaletra. Dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) is a commonly recommended regimen.
• Other Protease Inhibitors (e.g., Darunavir/ritonavir, Atazanavir/ritonavir): These are alternative boosted protease inhibitor regimens. Darunavir/ritonavir is generally preferred over lopinavir/ritonavir in treatment-experienced patients due to better tolerability and a higher genetic barrier to resistance.
• NNRTI-Based Regimens (e.g., Efavirenz, Rilpivirine): These are alternative regimens, but they have their own side effect profiles and interaction potentials. Rilpivirine is contraindicated with proton pump inhibitors and has specific food requirements.
• Entry Inhibitors (e.g., Maraviroc): Used only in patients with CCR5-tropic HIV, as determined by a tropism test. Less commonly used in initial therapy.

Comparison: Kaletra was once a cornerstone of HIV therapy, but its role has diminished in Canada with the availability of newer, better-tolerated agents. Integrase inhibitor-based regimens, such as dolutegravir plus NRTIs, are now the preferred first-line therapy due to their superior efficacy, favorable safety profile, and lower potential for drug interactions. However, Kaletra remains a valuable option in certain treatment-experienced patients, in resource-limited settings, and in patients with HIV strains that are resistant to other classes of antiretroviral drugs. It is also used for post-exposure prophylaxis in some settings. Your HIV specialist will determine the best regimen for your specific situation.

Legal Status, Registration, and Coverage in Canada

• Registration: Kaletra is authorized for sale in Canada by Health Canada as a prescription drug. The 200/50 mg tablet has DIN 02285533 and a status of "Marketed" with a status date of 2015-01-14. The 100/25 mg tablet has DIN 02312301 and a status of "Marketed" with a status date of 2014-11-25. The oral solution has DIN 02243644 and a status of "Marketed" with a status date of 2014-06-09. The manufacturer is AbbVie Corporation.
• Prescription Status: Prescription only in Canada.
• Coverage: Kaletra 200/50 mg tablets are listed as a General Benefit on the Ontario Drug Benefit (ODB) Formulary via the Facilitated Access Mechanism, with a drug benefit price of $6.0979 per tablet. In Quebec, Kaletra is covered under the RAMQ formulary (DIN 02285533 for the 200/50 mg tablet; DIN 02312301 for the 100/25 mg tablet; DIN 02243644 for the oral solution). In Alberta, lopinavir/ritonavir is covered under the Alberta Drug Benefit List. Coverage is also available under the Non-Insured Health Benefits (NIHB) program for eligible First Nations and Inuit clients. Generic formulations, if available, are generally more affordable than the brand-name product.
• Pharmacovigilance: Adverse reactions should be reported to Health Canada's MedEffect Canada program.

Recent Research and Clinical Guidelines (2022–2026)

• Current Canadian and international HIV treatment guidelines, including those from the Department of Health and Human Services (DHHS) and the Canadian AIDS Treatment Information Exchange (CATIE), no longer recommend protease inhibitor-based regimens such as lopinavir/ritonavir as preferred first-line therapy for most patients. Integrase inhibitor-based regimens are now the preferred first-line option due to superior efficacy and tolerability.
• Kaletra continues to be used as an alternative regimen in treatment-experienced patients with limited treatment options, in patients with HIV strains resistant to other classes, and in some resource-limited settings. It is also used for post-exposure prophylaxis (PEP) in certain protocols.
• A drug shortage of Kaletra oral solution was reported in Canada in 2024 due to manufacturing issues, with an anticipated return date in 2025. The tablet formulations were not affected by this shortage.
• Research continues to explore the role of protease inhibitors in HIV therapy, including long-acting injectable formulations and novel boosting strategies. However, the trend in HIV therapy continues to move away from protease inhibitors toward integrase inhibitors and other newer classes with better safety and tolerability profiles.
• No new safety signals or major changes to the risk-benefit profile of lopinavir/ritonavir have been identified in recent years. The product remains a well-established option in the HIV treatment armamentarium, but its use is declining in favor of newer agents.

Availability and Supply in Canada

Prices and availability may vary by province, territory, and pharmacy. Generic formulations may be available in some jurisdictions and are generally more affordable than the brand-name product. Kaletra is covered under most provincial and territorial drug plans and under the Non-Insured Health Benefits (NIHB) program. Check with your local pharmacy or HIV clinic for current pricing and availability.

Frequently Asked Questions (FAQ)

1. What is Kaletra used for?
   Kaletra is a prescription medicine used to treat HIV-1 infection in adults and children 14 days of age and older. It is always used in combination with other antiretroviral medicines. It helps lower the amount of HIV in your blood (viral load) and improves your immune system (CD4+ count), reducing the risk of HIV-related complications.
2. How does Kaletra work?
   Kaletra contains two medicines: lopinavir and ritonavir. Lopinavir is the active antiviral that stops the HIV virus from making copies of itself by blocking an enzyme the virus needs to mature. Ritonavir is a booster that blocks the liver from breaking down lopinavir, keeping its levels high in the blood so it can work effectively around the clock.
3. How should I take Kaletra?
   Take Kaletra exactly as prescribed by your HIV specialist. The standard dose is two 200/50 mg tablets twice daily, approximately 12 hours apart. Swallow the tablets whole with a full glass of water. You can take the tablets with or without food. Do not miss doses, as missing doses can lead to HIV resistance.
4. Can I take Kaletra with food?
   Yes. Kaletra 200/50 mg tablets can be taken with or without food. However, the oral solution must be taken with food to ensure adequate absorption.
5. What should I do if I miss a dose?
   If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
6. Can I drink alcohol while taking Kaletra?
   No. Alcohol should not be consumed while taking Kaletra because it may worsen liver-related side effects and increase the risk of pancreatitis.
7. What are the serious side effects of Kaletra?
   Serious side effects include pancreatitis (severe abdominal pain), liver damage (yellowing of skin or eyes, dark urine), heart rhythm changes (QT prolongation), and severe allergic reactions. Seek immediate medical attention if you experience these symptoms.
8. Is Kaletra safe during pregnancy?
   Kaletra should be used during pregnancy only if clearly needed. Once-daily dosing is not recommended during pregnancy. Consult your HIV specialist if you are pregnant or planning to become pregnant.
9. Is Kaletra safe during breastfeeding?
   It is not known whether lopinavir is excreted in human breast milk. Mothers with HIV should not breastfeed to avoid transmission of HIV to the infant. Consult your HIV specialist for guidance.
10. Are there alternatives to Kaletra?
    Yes. Integrase inhibitor-based regimens, such as dolutegravir plus two nucleoside reverse transcriptase inhibitors, are now preferred first-line regimens due to superior efficacy and better tolerability. Other alternatives include darunavir/ritonavir and NNRTI-based regimens. Your HIV specialist will determine the best regimen for your specific situation.
11. Is Kaletra covered by Canadian health insurance?
    Kaletra is covered under most provincial and territorial drug plans, including the Ontario Drug Benefit (ODB) Formulary and the RAMQ formulary in Quebec. It is also covered under the Non-Insured Health Benefits (NIHB) program for eligible First Nations and Inuit clients. Check with your provincial drug plan and private insurance provider for coverage details.